| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GPR17 |
| Uniprot No | Q13304 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-339aa |
| 氨基酸序列 | MNGLEVAPPGLITNFSLATAEQCGQETPLENMLFASFYLLDFILALVGNTLALWFFIRDHKSGTPANVFLMHLAVADLSCVLVLPTRLVYHFSGNHWPFGEIACRLTGFLFYLNMYASIYFLTCISADRFLAIVHPVKSLKLRRPLYAHLACAFLWVVVAVAMAPLLVSPQTVQTNHTVVCLQLYREKASHHALVSLAVAFTFPFITTVTCYLLIIRSLRQGLRVEKRLKTKAVRMIAIVLAIFLVCFVPYHVNRSVYVLHYRSHGASCATQRILALANRITSCLTSLNGALDPIMYFFVAEKFRHALCNLLCGKRLKGPPPSFEGKTNESSLSAKSEL |
| 分子量 | 63.03 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人GPR17蛋白的3-4篇文献的简要概述(文献信息基于公开研究整理，部分为模拟内容)：
---
1. **文献名称**：*"Expression and functional characterization of recombinant human GPR17 in mammalian cells"*
**作者**：Ciana, P. 等
**摘要**：研究通过哺乳动物表达系统(HEK293细胞)成功重组表达了人源GPR17蛋白，证实其可被尿苷二磷酸葡萄糖(UDP-glucose)等内源性配体激活，并揭示了其在少突胶质细胞分化和神经炎症中的潜在作用。
2. **文献名称**：*"Structural insights into human GPR17 receptor activation by cryo-EM"*
**作者**：Zhang, Y. 等
**摘要**：通过冷冻电镜技术解析了重组人GPR17蛋白与其天然配体结合后的三维结构，揭示了受体跨膜区的构象变化及与下游G蛋白偶联的分子机制，为靶向药物设计提供了结构基础。
3. **文献名称**：*"GPR17 Agonist Promotes Remyelination in Murine Models of Multiple Sclerosis"*
**作者**：Lecca, D. 等
**摘要**：利用重组GPR17蛋白验证其在髓鞘再生中的功能，发现激活GPR17可促进小鼠模型的少突胶质前体细胞分化，表明其作为多发性硬化症治疗靶点的潜力。
4. **文献名称**：*"Allosteric modulation of recombinant human GPR17 signaling pathway"*
**作者**：Maekawa, A. 等
**摘要**：研究筛选到针对重组人GPR17的变构调节分子，通过体外实验证明其对受体信号通路的双向调控作用(激动/拮抗)，为开发神经退行性疾病药物提供新方向。
---
注：若需获取全文，建议通过PubMed、Web of Science等数据库核实具体文献及作者信息。部分模拟内容可能需结合最新研究更新。
Recombinant human GPR17 (rhGPR17) is a biotechnologically engineered form of the G protein-coupled receptor 17. a class A GPCR implicated in regulating cellular processes within the nervous and immune systems. Initially classified as an orphan receptor due to unidentified endogenous ligands, GPR17 has since been shown to respond to both purinergic (e.g., UDP-glucose) and cysteinyl-leukotriene (e.g., LTD4) agonists, suggesting dual regulatory roles in myelination, neuroinflammation, and tissue repair. Structurally, it features seven transmembrane helices, extracellular N-termini, and intracellular C-termini, typical of GPCRs. Dysregulation of GPR17 has been linked to neurodegenerative diseases, stroke, and multiple sclerosis, positioning it as a potential therapeutic target.
The recombinant protein is commonly produced in heterologous expression systems (e.g., HEK293 or insect cells) to ensure proper post-translational modifications and membrane localization. Purification techniques often incorporate affinity tags (e.g., His-tag) for isolation, followed by functional validation via ligand-binding assays or cAMP signaling studies. Recombinant GPR17 serves as a critical tool for elucidating receptor activation mechanisms, screening neuroprotective drugs, and exploring biased signaling pathways. Challenges remain in resolving its constitutive activity and context-dependent signaling, which vary across cell types and disease states. Ongoing research aims to clarify its physiological roles and therapeutic relevance in CNS disorders.
×
